Prof. Dr. Cafer Adıgüzel Artikuj
A1. Kantarcioglu B, Iqbal O, Lewis J, Carter CA, Singh M, Lievano F, Ligocki M, Jeske W, Adiguzel C, Gerotziafas GT, Fareed J.An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clin Appl Thromb Hemost. 2022 Jan-Dec;28
A2. Umit EG, Kara O, Adiguzel C. (Re: Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020; 36(1):33-41. Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36(1):43-50.) Curr Med Res Opin. 2020 Apr;36(4):607.
A3. Yabas Kiziloglu O, Mestanoglu M, Totuk Gedar OM, Adiguzel C, Toygar O. Recurrence of acute lymphoblastic leukemia manifesting as serous retinal detachments and optic disc swelling.Int Ophthalmol. 2018 Aug;38(4):1791-1795.
A4. Kantarcıoğlu B, Türköz HK, Yılmaz G, Pepedil Tanrıkulu F, Kaygusuz Atagündüz I, Adıgüzel C, Fıratlı Tuğlular T. Aplastic anemia associated with oral terbinafine: a case report and review of the literature. Turk J Haematol. 2014 Dec 5;31(4):411-6.
A5. Toptas T, Kaygusuz-Atagunduz I, Kani HT, Adiguzel C, Firatli-Tuglular T. Levofloxacin for the treatment of severe refractory BK virus-associated hemorrhagic cystitis in hematopoietic stem cell transplantation recipients: A report of three cases. Oncol Lett. 2014 Oct;8(4):1775-1777.
A6. Fareed J, Adiguzel C, Thethi I.Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J. 2011 Mar 28;9(1):5.
A7. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract . 64(7):956-67 (2010).
A8. Kaygusuz I, Koc M, Arikan H, Adiguzel C, Cakalagaoglu F, Tuglular TF, Akoglu E. Focal segmental glomerulosclerosis associated with idiopathic myelofibrosis. Ren Fail. 32(2):273-6 (2010).
A9. Knesek MJ, Litinas E, Adiguzel C, Hopkinson W, Hoppensteadt D, Lassen M, Fareed J. Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins. Clin Appl Thromb Hemost. 16(1):42-50 (2010).
A10. Zhu H, Hoppensteadt D, Iqbal O, Litinas E, Adiguzel C, Fareed J. Relative purity of different bovine thrombin preparations. Clin Appl Thromb Hemost. 15(6):681-8 (2009).
A11. Adiguzel C, Iqbal O, Demir M, Fareed J. European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost. 15(6):645-51 (2009).
A12. Sayitoglu, M., I.C. Haznedaroğlu, O. Hatirnaz, Y. Erbilgin, S. Aksu, E. Koca, C. Adiguzel, M. Bayik, I. Akalin, Z. Gülbas, M. Akay, A. Unal, L. Kaynar, E. Ovali, M. Yilmaz, M. Yenerel, S. Dagdas, G. Ozet, C. Ar, Y. Aydin, T. Soysal, B. Durgun, O. Ozcebe, A. Tukun, O. Ilhan ve U.Ozbek. “Effects of Imatinib Mesylate on Renin-Angiotensin System (RAS) Activity During the Clinical Course of Chronic Myeloid Leukaemia” J Int Med Res, 37, 1018-1028 (2009).
A13. Adiguzel, C., O. Iqbal, D. Hoppensteadt, W. Jeske, J. Cunanan, E. Litinas, H. Zhu, J.M. Walenga ve J. Fareed. “Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide”. Clin Appl Thromb Hemost, 15(5):501-11. (2009).
A14. Kannan, M., R. Saxena, C. Adiguzel ve J. Fareed. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. Semin Thromb Hemost , 35, 337-343 (2009).
A15. Adiguzel, C., V. Bansal, E. Litinas, J. Cunanan, O. Iqbal, K. Nelson, M. Kannan, D. Hoppensteadt ve J. Fareed. “Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin”. Clin Appl Thromb Hemost, 15, 145-151 (2009).
A16. Adiguzel, C., W.P. Jeske, D. Hoppensteadt, J.M. Walenga, V. Bansal ve Fareed J. “Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products”. Clin Appl Thromb Hemost, 15, 137-144 (2009).
A17. Adiguzel, C., S.U. Bozkurt, I. Kaygusuz, A. Uzay, Tecimer T, ve M. Bayik. “Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature”. APMIS, 117, 222-229 (2009).
A18. Heilmann, L., M. Schorch, T. Hahn, G. Adasz, K. Schilberz, C. Adiguzel ve J. Fareed. “Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study”. Semin Thromb Hemos. 34, 794-802 (2008).
A19. Zhu, H., D. Hoppensteadt, C. Adiguzel, R.L. Bick ve J. Fareed. “Comparison of immunogenic potentials of bovine thrombin preparations”. Clin Appl Thromb Hemost, 15, 41-49 (2009).
A20. Zhu, H., D. Hoppensteadt, R. Wahi, J. Cunanan, C. Adiguzel, R. Bick ve J. Fareed. “Reduced Immunogenic Potential of Membrane Filtered Bovine Thrombin Preparations for Hemostatic Application”. Clin Appl Thromb Hemost, 15, 32-40 (2009).
A21. Clark, M., D. Hoppensteadt, J. Walenga, L. Myers, J. Cunanan, W. Jeske, C. Adiguzel, O. Iqbal ve J. Fareed. “Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate”. Int Angiol, 27, 370-376 (2008).
A22. Iqbal, O., C. Adiguzel, B.E. Lewis, J. Cunanan ve J. Fareed. “Argatroban in percutaneous Coronary interventions”. Semin Thromb Hemost, 34(Suppl 1), 62-74 (2008).
A23. Adiguzel, C., O. Iqbal, J. Cunanan, W. Jeske, D. Hoppensteadt, J.M. Walenga ve J. Fareed. “Potency adjusted generic versions of argatroban can be differentiated from branded argatroban in thrombin generation and platelet activation assays”. Semin Thromb Hemost, 34(Suppl 1), 108-117 (2008).
A24. Fareed, J., J.M. Walenga, W. Jeske, D. Hoppensteadt, M. Prechel, O. Iqbal, C. Adiguzel, M. Clark, E. Litinas, J. Cunanan, R. Linhardt ve J. Harenberg. “Biological profile of the hyper/oversulfated chondroitin sulfate contaminant isolated from recall heparin”. Semin Thromb Hemost, 34(Suppl 1), 119-127 (2008).
A25. Fareed, J., W. Jeske, D. Fareed, M. Clark, R. Wahi, C. Adiguzel ve D. Hoppensteadt. “Are all low molecular weight heparins equivalent in the management of venous thromboembolism?” Clin Appl Thromb Hemost, 14, 385-392 (2008).
A26. Hoppensteadt, D.A., R. Wahi, C. Adiguzel, O. Iqbal, E. Ramacciotti, R.L. Bick, H.L. Messmore, V. Bansal ve Fareed J. “Contaminant in the recalled unfractionated heparin preparations: where is the problem?” Clin Appl Thromb Hemost, 14, 261-266 (2008).
A27. Fareed, J., O. Iqbal, J. Cunanan, M. Demir, R. Wahi, M. Clarke, C. Adiguzel ve R. Bick. “Chaining trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?” Int Angiol, 27, 176-192 (2008).
A28. Fareed, J., D.A. Hoppensteadt, D. Fareed, M. Demir, R. Wahi, M. Clarke, C. Adiguzel ve R. Bick. “Survival of heparins, oral anticoagulants, and aspirin after the year 2010”. Semin Thromb Hemost, 34, 58-73 (2008).
A29. Jeske, W.P., J.M. Walenga, D.A. Hoppensteadt, C. Vandenberg, A. Brubaker, C. Adiguzel, M. Bakhos ve J. Fareed. “Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic”. Semin Thromb Hemost, 34, 74-85 (2008).
A30. Hoppensteadt, D.A., N. Fabbrini, R.L. Bick, H.L. Messmore, C. Adiguzel, J. Fareed. “Laboratory evaluation of the antiphospholipid syndrome”. Hematol Oncol Clin North Am, 22, 19-32 (2008).
A31. Bizargity, P., C. Adıguzel, G. Ozilhan, M. Bayık ve E. Eksioglu-Demiralp. “İmatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia”. Clin Lab Haem: 27:1-2 (2005).
A32. Cetiner, M., C. Adıgüzel, D. Argon, S. Ratip, E. Ekşioğlu-Demiralp, T. Tecimer ve M. Bayık. “Hairy Cell Leukemia in Father and Son”. Med Oncol, 20, 375-378 (2003).
A33. Demirçay, Z., A. Cömert ve C. Adıgüzel. “Leg Ulsers and Hydroxyurea: Report of Three Cases with Essential Thrombocythemia”. İnternational Journal of Dermatology, 41, 872-874 (2002).
